Personal Genome Diagnostics and QIAGEN Collaborate to Offer Integrated Genomic Testing and Interpretation Support

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, announced today that it has entered into a collaboration with QIAGEN to provide comprehensive genomic profiling tests and clinical decision support to molecular labs.

Under the non-exclusive agreement, PGDx will be responsible for the distribution of the PGDx eliotm oncology products and kitted solutions. Laboratories that purchase the PGDx elio products will have an option to receive from QIAGEN standardized reporting, driven by professional guidelines for streamlined case review and sign-out. In addition, laboratories will receive access to QIAGEN's QCI Interpret One for rapid, evidence-based reporting for next-generation sequencing (NGS) oncology tests at scale. Advancing cancer diagnostics and making precision medicine more accessible to healthcare systems, laboratories, and patients worldwide is a key focus of both parties.

Cancer guidelines increasingly call for comprehensive molecular profiling to optimize treatment planning and inform care. PGDx elio tissue complete, the first FDA-cleared comprehensive genomic profiling kit, is used to identify alterations in the tumor and inform treatment decisions for patients with advanced solid tumors. QCI Interpret One enables clinical labs to deliver oncologist-ready variant interpretation reports from NGS tests faster and with greater precision than ever before. The kitted PGDx system allows molecular laboratories anywhere to perform this advanced genomic testing of cancer in a more efficient, standardized, and accurate manner. By providing tests and interpretation support that can be run locally and automating the data analysis process, PGDx and QIAGEN are enabling the adoption of precision medicine in healthcare systems across the country, no matter where a patient seeks treatment.

"PGDx elio tissue complete is a first of its kind FDA cleared kit to enable any molecular lab to perform comprehensive tumor profiling. It is important for our customers to be able to stay up to date with clinical guidelines and evidence supporting variant interpretation to maximize the value of NGS data in improving clinical care," said Megan Bailey, Chief Executive Officer of PGDx. "We've built the PGDx elio software to deliver robust, high quality variant calls. The addition of QIAGEN clinical decision support software for our customers provides labs an option for a comprehensive solution that will enable more informed treatment decisions for clinicians and patients."

About Personal Genome Diagnostics

Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome. We are committed to improving clinical insight, speed of results, and healthcare economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic products for health systems worldwide. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. For additional information, visit www.pgdx.com.